102 related articles for article (PubMed ID: 8542048)
1. Hereditary nondystrophic myotonias and periodic paralyses.
Lehmann-Horn F; Rüdel R
Curr Opin Neurol; 1995 Oct; 8(5):402-10. PubMed ID: 8542048
[TBL] [Abstract][Full Text] [Related]
2. Diagnostics in skeletal muscle channelopathies.
Vicino A; Brugnoni R; Maggi L
Expert Rev Mol Diagn; 2023; 23(12):1175-1193. PubMed ID: 38009256
[TBL] [Abstract][Full Text] [Related]
3. Treatment of neuromuscular channelopathies: current concepts and future prospects.
Cleland JC; Griggs RC
Neurotherapeutics; 2008 Oct; 5(4):607-12. PubMed ID: 19019313
[TBL] [Abstract][Full Text] [Related]
4. Treatment Updates for Neuromuscular Channelopathies.
Jitpimolmard N; Matthews E; Fialho D
Curr Treat Options Neurol; 2020; 22(10):34. PubMed ID: 32848354
[TBL] [Abstract][Full Text] [Related]
5. Skeletal muscle channelopathies: a guide to diagnosis and management.
Matthews E; Holmes S; Fialho D
Pract Neurol; 2021 Jun; 21(3):196-204. PubMed ID: 33563766
[TBL] [Abstract][Full Text] [Related]
6. Long-term Safety and Efficacy of Mexiletine in Myotonic Dystrophy Types 1 and 2.
Mousele C; Matthews E; Pitceathly RDS; Hanna MG; MacDonald S; Savvatis K; Carr A; Turner C
Neurol Clin Pract; 2021 Oct; 11(5):e682-e685. PubMed ID: 34840883
[TBL] [Abstract][Full Text] [Related]
7. Cannabidiol inhibits the skeletal muscle Nav1.4 by blocking its pore and by altering membrane elasticity.
Ghovanloo MR; Choudhury K; Bandaru TS; Fouda MA; Rayani K; Rusinova R; Phaterpekar T; Nelkenbrecher K; Watkins AR; Poburko D; Thewalt J; Andersen OS; Delemotte L; Goodchild SJ; Ruben PC
J Gen Physiol; 2021 May; 153(5):. PubMed ID: 33836525
[TBL] [Abstract][Full Text] [Related]
8. Changes in Resurgent Sodium Current Contribute to the Hyperexcitability of Muscles in Patients with Paramyotonia Congenita.
Huang CW; Lai HJ; Lin PC; Lee MJ
Biomedicines; 2021 Jan; 9(1):. PubMed ID: 33430134
[TBL] [Abstract][Full Text] [Related]
9. Genotype-Phenotype Correlations and Characterization of Medication Use in Inherited Myotonic Disorders.
Meyer AP; Roggenbuck J; LoRusso S; Kissel J; Smith RM; Kline D; Arnold WD
Front Neurol; 2020; 11():593. PubMed ID: 32670189
[No Abstract] [Full Text] [Related]
10. Guidelines on clinical presentation and management of nondystrophic myotonias.
Stunnenberg BC; LoRusso S; Arnold WD; Barohn RJ; Cannon SC; Fontaine B; Griggs RC; Hanna MG; Matthews E; Meola G; Sansone VA; Trivedi JR; van Engelen BGM; Vicart S; Statland JM
Muscle Nerve; 2020 Oct; 62(4):430-444. PubMed ID: 32270509
[TBL] [Abstract][Full Text] [Related]
11. A Mixed Periodic Paralysis & Myotonia Mutant, P1158S, Imparts pH-Sensitivity in Skeletal Muscle Voltage-gated Sodium Channels.
Ghovanloo MR; Abdelsayed M; Peters CH; Ruben PC
Sci Rep; 2018 Apr; 8(1):6304. PubMed ID: 29674667
[TBL] [Abstract][Full Text] [Related]
12. Mutation analysis in exons 22 and 24 of SCN4A gene in Iranian patients with non-dystrophic myotonia.
Heidari MM; Khatami M; Nafissi S; Hesami-Zokai F; Khorrami A
Iran J Neurol; 2015 Oct; 14(4):190-4. PubMed ID: 26885337
[TBL] [Abstract][Full Text] [Related]
13. Defective fast inactivation recovery of Nav 1.4 in congenital myasthenic syndrome.
Arnold WD; Feldman DH; Ramirez S; He L; Kassar D; Quick A; Klassen TL; Lara M; Nguyen J; Kissel JT; Lossin C; Maselli RA
Ann Neurol; 2015 May; 77(5):840-50. PubMed ID: 25707578
[TBL] [Abstract][Full Text] [Related]
14. Muscle channelopathies: the nondystrophic myotonias and periodic paralyses.
Statland JM; Barohn RJ
Continuum (Minneap Minn); 2013 Dec; 19(6 Muscle Disease):1598-614. PubMed ID: 24305449
[TBL] [Abstract][Full Text] [Related]
15. Rosiglitazone inhibits Kv4.3 potassium channels by open-channel block and acceleration of closed-state inactivation.
Jeong I; Choi BH; Hahn SJ
Br J Pharmacol; 2011 Jun; 163(3):510-20. PubMed ID: 21232039
[TBL] [Abstract][Full Text] [Related]
16. Skeletal muscle channelopathies: new insights into the periodic paralyses and nondystrophic myotonias.
Platt D; Griggs R
Curr Opin Neurol; 2009 Oct; 22(5):524-31. PubMed ID: 19571750
[TBL] [Abstract][Full Text] [Related]
17. The nondystrophic myotonias.
Heatwole CR; Moxley RT
Neurotherapeutics; 2007 Apr; 4(2):238-51. PubMed ID: 17395134
[TBL] [Abstract][Full Text] [Related]
18. Structural requirements for voltage-dependent block of muscle sodium channels by phenol derivatives.
Haeseler G; Piepenbrink A; Bufler J; Dengler R; Aronson JK; Piepenbrock S; Leuwer M
Br J Pharmacol; 2001 Apr; 132(8):1916-24. PubMed ID: 11309264
[TBL] [Abstract][Full Text] [Related]
19. Voltage-dependent blockade of normal and mutant muscle sodium channels by benzylalcohol.
Haeseler G; Mamarvar M; Bufler J; Dengler R; Hecker H; Aronson JK; Piepenbrock S; Leuwer M
Br J Pharmacol; 2000 Jul; 130(6):1321-30. PubMed ID: 10903972
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
